X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TEVA PHARMA (Israel) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   TEVA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
TEVA PHARMA
Dec-13
SANOFI INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5602,709-   
Low Rs4,4002,353-   
Sales per share (Unadj.) Rs1,028.51,554.5-  
Earnings per share (Unadj.) Rs129.097.1-  
Cash flow per share (Unadj.) Rs186.0222.8-  
Dividends per share (Unadj.) Rs68.0085.01-  
Dividend yield (eoy) %1.53.4 45.2%  
Book value per share (Unadj.) Rs753.61,726.7-  
Shares outstanding (eoy) m23.03848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.6 267.6%   
Avg P/E ratio x34.726.1 133.3%  
P/CF ratio (eoy) x24.111.4 212.0%  
Price / Book Value ratio x5.91.5 405.6%  
Dividend payout %52.787.5 60.2%   
Avg Mkt Cap Rs m103,1742,146,042 4.8%   
No. of employees `0003.644.9 8.1%   
Total wages/salary Rs m3,5920-   
Avg. sales/employee Rs Th6,537.729,328.6 22.3%   
Avg. wages/employee Rs Th991.40-   
Avg. net profit/employee Rs Th819.81,832.1 44.7%   
INCOME DATA
Net Sales Rs m23,6861,318,175 1.8%  
Other income Rs m7080-   
Total revenues Rs m24,3941,318,175 1.9%   
Gross profit Rs m5,281360,983 1.5%  
Depreciation Rs m1,313106,549 1.2%   
Interest Rs m1525,891 0.1%   
Profit before tax Rs m4,661228,543 2.0%   
Minority Interest Rs m01,038 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m1,691-2,790 -60.6%   
Profit after tax Rs m2,97082,345 3.6%  
Gross profit margin %22.327.4 81.4%  
Effective tax rate %36.3-1.2 -2,971.6%   
Net profit margin %12.56.2 200.7%  
BALANCE SHEET DATA
Current assets Rs m15,673890,291 1.8%   
Current liabilities Rs m6,678776,409 0.9%   
Net working cap to sales %38.08.6 439.6%  
Current ratio x2.31.1 204.7%  
Inventory Days Days7691 83.7%  
Debtors Days Days2296 23.3%  
Net fixed assets Rs m8,098430,545 1.9%   
Share capital Rs m2303,245 7.1%   
"Free" reserves Rs m17,0880-   
Net worth Rs m17,3561,464,243 1.2%   
Long term debt Rs m0674,012 0.0%   
Total assets Rs m25,4003,012,453 0.8%  
Interest coverage x311.79.8 3,172.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.4 213.1%   
Return on assets %11.83.6 327.1%  
Return on equity %17.15.6 304.3%  
Return on capital %26.94.9 546.3%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,226210,049 1.5%  
From Investments Rs m-1,555-74,429 2.1%  
From Financial Activity Rs m-1,818-251,968 0.7%  
Net Cashflow Rs m-147-116,348 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare SANOFI INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SANOFI INDIA With: ALKEM LABORATORIES  TORRENT PHARMA  PFIZER  WOCKHARDT LTD.  CADILA HEALTHCARE  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS